---
document_datetime: 2025-01-31 16:12:12
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vaxchora-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: vaxchora-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.2969141
conversion_datetime: 2025-12-28 19:18:42.652713
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Vaxchora

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                  |
|----------------------|---------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10862 /202406  | Periodic Safety Update EU Single assessment - cholera vaccine, oral, live | 16/01/2025                          | n/a                                         |                                  | PRAC Recommendation - maintenance                                                                                                                                        |
| R/0024               | Renewal of the marketing authorisation.                                   | 14/11/2024                          | 13/01/2025                                  | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Vaxchora in the approved indication remains favourable |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                        | and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------|
| IB/0027             | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                                                                                                                                                      | 10/12/2024 | n/a        |                        |                                                                                                 |
| IA/0026             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                         | 21/11/2024 | n/a        |                        |                                                                                                 |
| PSUSA/10862 /202306 | Periodic Safety Update EU Single assessment - cholera vaccine, oral, live                                                                                                                                                                                                                                                                                                                                    | 11/01/2024 | n/a        |                        | PRAC Recommendation - maintenance                                                               |
| IA/0023/G           | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 12/12/2023 | 13/01/2025 | Annex II               |                                                                                                 |
| T/0021              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                          | 16/08/2023 | 22/09/2023 | SmPC, Labelling and PL |                                                                                                 |
| II/0020             | B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test                                                                                                                                                                                                           | 14/09/2023 | n/a        |                        |                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                     | method at the site is a biol/immunol method                                                                                                                                                                                                                                                                                                                     |            |     |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0019/G           | This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method                        | 03/05/2023 | n/a |                                   |
| IB/0018/G           | This was an application for a group of variations. B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time | 27/02/2023 | n/a |                                   |
| PSUSA/10862 /202206 | Periodic Safety Update EU Single assessment - cholera vaccine, oral, live                                                                                                                                                                                                                                                                                       | 12/01/2023 | n/a | PRAC Recommendation - maintenance |
| IB/0016             | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                     | 22/12/2022 | n/a |                                   |
| IA/0017             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                            | 16/12/2022 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| II/0013             | Type II - C.I.4, to update Section 6.6 of the SmPC to add the use of carbonated bottled water to reconstitute the vaccine in addition to non- carbonated bottled water. The package leaflet and labelling are updated accordingly. The applicant took the opportunity to submit a corrected Annex A in all languages, which currently presents an inconsistency in the way the strength was stated at MAA approval (as detailed in SmPC). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 21/07/2022   | 04/07/2023   | SmPC, Labelling and PL   | The SmPC section 6.6 has been updated as follows: to add the use of carbonated bottled water to reconstitute the vaccine in addition to non-carbonated bottled water The PL have been updated accordingly.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10862 /202112 | Periodic Safety Update EU Single assessment - cholera vaccine, oral, live                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 07/07/2022   | n/a          |                          | PRAC Recommendation - maintenance                                                                                                                                                                            |
| IB/0014             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                 | 20/05/2022   | n/a          |                          |                                                                                                                                                                                                              |
| IB/0011/G           | This was an application for a group of variations. B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                      | 10/02/2022   | n/a          |                          |                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| PSUSA/10862 /202106   | Periodic Safety Update EU Single assessment - cholera vaccine, oral, live                                                                                                                                                                                                                           | 13/01/2022   | n/a        |                                  | PRAC Recommendation - maintenance                                      |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|------------------------------------------------------------------------|
| IB/0010               | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                              | 22/12/2021   | n/a        |                                  |                                                                        |
| II/0009               | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                                                                 | 16/12/2021   | n/a        |                                  |                                                                        |
| PSUSA/10862 /202012   | Periodic Safety Update EU Single assessment - cholera vaccine, oral, live                                                                                                                                                                                                                           | 08/07/2021   | n/a        |                                  | PRAC Recommendation - maintenance                                      |
| IA/0007               | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                       | 04/05/2021   | 02/08/2022 | Annex II and PL                  |                                                                        |
| II/0003/G             | This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 28/01/2021   | 26/02/2021 | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion 'Vaxchora-H-C-003876- II-0003-G' |
| PSUSA/10862 /202006   | Periodic Safety Update EU Single assessment - cholera vaccine, oral, live                                                                                                                                                                                                                           | 14/01/2021   | n/a        |                                  | PRAC Recommendation - maintenance                                      |
| IB/0005               | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other                                                                                                                                                                                                       | 05/01/2021   | n/a        |                                  |                                                                        |

<div style=\"page-break-after: always\"></div>

|           | changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                        |            |            |                 |                |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------|
| IB/0002/G | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change stability protocol | 29/06/2020 | n/a        |                 | to an approved |
| IAIN/0001 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                            | 20/05/2020 | 26/02/2021 | Annex II and PL |                |